Ironwood Pharma (IRWD) Misses Q1 EPS by 1c; Offers FY23 Revenue Guidance

Ironwood Pharma (NASDAQ: IRWD) reported Q1 EPS of $0.25, $0.01 worse than the analyst estimate of $0.26. Revenue for the quarter came in at $104.06 million versus the consensus estimate of $100.3 million.

GUIDANCE:

Ironwood Pharma sees FY2023 revenue of $420-435 million, versus the consensus of $426.4 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• Unum Group (UNM) PT Raised to $94 at UBS on Second LTC Deal
• UBS Reiterates Buy Rating on Smurfit Westrock (SW)